NCT00102141 - Effect of Angeliq on Blood Pressure (BP) in Postmenopausal Hypertensive Women | Biotech Hunter

Enrollment

750

Participants

Timeline

Start Date

April 30, 2004

Study Completion Date

July 31, 2005

Conditions

HypertensionPostmenopause

Interventions

DRUG

Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)

Drospirenone 3 mg + 1mg 17ß-estradiol, given as tablets orally once daily in the morning for 8 weeks

DRUG

Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)

Drospirenone 2 mg + 1mg 17ß-estradiol, given as tablets orally once daily in the morning for 8 weeks

DRUG

Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)

Drospirenone 1 mg + 1mg 17ß-estradiol, given as tablets orally once daily in the morning for 8 weeks

DRUG

Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)

1mg 17ß-estradiol, given as tablets orally once daily in the morning for 8 weeks

DRUG

Placebo

Placebo, given as tablets orally once daily in the morning for 8 weeks